SCHEMBL4892059

SCHEMBL4892059

Nc1nc(C#CC2=CCCCC2)cs1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.48
CYP1A2 P05177 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.35
ALOX15 P16050 2/20 0.35
RAB9A P51151 2/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
FFAR1 O14842 1/20 0.34
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
NOS1 P29475 1/20 0.32
ALK Q9UM73 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893360 0.82 GRM5 (0.37) GRM5CYP1A2SMN1; SMN2ALDH1A1MAPT
SCHEMBL4855973 0.81 GRM5 (0.48) GRM5CYP1A2
SCHEMBL7420431 0.69 ALK (0.49) GRM5CYP1A2SMN1; SMN2ALOX15RAB9A
SCHEMBL4865167 0.68 GRM5 (0.46) GRM5CYP1A2
SCHEMBL4855899 0.66 GRM5 (0.59) GRM5CYP1A2SMN1; SMN2ALOX15RAB9A
SCHEMBL6312183 0.65 GRM5 (0.69) GRM5CYP1A2SMN1; SMN2RAB9AALDH1A1
SCHEMBL22049321 0.65 CYP1A2 (0.42) GRM5CYP1A2RAB9ANPC1FFAR1
SCHEMBL4854401 0.65 GRM5 (0.50) GRM5CYP1A2RAB9ANPC1FFAR1
SCHEMBL4150082 0.64 GRM5 (0.46) GRM5SMN1; SMN2RAB9AHSD17B10ALDH1A1
SCHEMBL4864468 0.64 GRM5 (0.97) GRM5CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462619-B2 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK & CO., INC. (US) 2008-12-09 US disclosed
US-7365074-B2 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK & CO., INC. (US) 2008-04-29 US disclosed
US-20050245542-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK SHARP & DOHME CORP. 2005-11-03 US disclosed
US-20050085523-A1 Imidazolyl and pyrazolyl ethyne compounds COSFORD NICHOLAS D (US) 2005-04-21 US disclosed
US-20050043307-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK SHARP & DOHME CORP. 2005-02-24 US disclosed
US-6774138-B2 TO FUNCTION AS AGONISTS OR ANTAGONISTS OF RECEPTORS FOR NEUROTRANSMITTERS, NEUROHORMONES AND NEUROMODULATORS, AS INSECTICIDES AND FINGICIDES MERCK & CO., INC. 2004-08-10 US disclosed
US-20030055247-A1 Thiazolyl(pyridyl)ethyne compounds MERCK SHARP & DOHME CORP. 2003-03-20 US disclosed
EP-1214303-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Merck & Co., Inc. (US) 2002-06-19 EP disclosed
WO-2001016121-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF MERCK & CO., INC. (US) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055247-A1 Thiazolyl(pyridyl)ethyne compounds CBR3, CBR1, CHRM3 GRM5 54/4885CYP1A2 125/4885SMN1; SMN2 1976/4885
US-20050043307-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds CBR3, P2RX5, CBR1 GRM5 45/4885CYP1A2 71/4885SMN1; SMN2 1825/4885
US-20050085523-A1 Imidazolyl and pyrazolyl ethyne compounds CBR3, CBR1, CHRM3 GRM5 67/4885CYP1A2 98/4885SMN1; SMN2 1649/4885
US-20050245542-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds P2RX5, P2RY12, P2RY4 GRM5 52/4885CYP1A2 76/4885SMN1; SMN2 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.